Skip to content

Sero-surveillance for Dengue, Chikungunya and COVID

Establish serial sero-surveillance to monitor the trend of SARS-CoV-2, Dengue and Chikungunya infection transmission in the general population, India

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/11/029141
Enrollment
5000
Registered
2020-11-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Shikha Dixit
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Survey will be carried out in individuals above 2 years of age (no upper limit on age) and all individuals currently residing and likely to stay till the end of study (1 year) in the study area will be considered eligible for inclusion.

Exclusion criteria

Exclusion criteria: Individuals who are unlikely to stay in the study area for the next 1 year

Design outcomes

Primary

MeasureTime frame
Primary objectives I. Estimate the sero-prevalence of SARS-CoV-2 infection in the general population II. Estimate the 4 monthly incidence of SARS-CoV-2 infection based on serial sero-surveys III. Estimate cumulative sero-conversion of SARS-CoV-2 infection over one year period IV. Estimate the sero-prevalence and annual sero conversion of Dengue and Chikungunya in a sub sample of the studyTimepoint: Sero-prevalence of COVID will be assessed at baseline, 4 months, 8 months and 12 months

Secondary

MeasureTime frame
Secondary objectives I. Monitor the trend of SARS-CoV-2 transmission in the general population II. Determine the prevalence and incidence of SARS CoV2 sero-positivity among the members of the households with at least one seropositive individual (clustering of infection at household level) Determine the risk factors for SARS-CoV-2 infection III. Determine the duration of persistence of antibodies in individuals tested positive for SARS-CoV-2 infection Timepoint: Trend of infection and duration of persistence of antibodies will be monitored by the serial sero-surveys at 0,4,8 and 12 months. Incidence of symptomatic infections will be assessed via fortnightly phone calls.

Countries

India

Contacts

Public ContactDivya Nair

The INCLEN Trust International

divya.nair@inclentrust.org8056748342

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026